Longitudinal Bladder Cancer Study for Tumour Recurrence

Status: active

Surveillance for recurrence of urothelial carcinoma (UC) requires frequent cystoscopy, which is invasive, expensive and time-consuming. An accurate urinary biomarker has the potential to reduce the number of cystoscopies required during post-treatment surveillance. This is a prospective, single arm, multi-center study using the diagnostic CxBladder test with subjects previously diagnosed with primary or recurrent UC and who are undergoing a schedule of investigative cystoscopies and treatment for the possible recurrence of UC presenting to qualified sites. To evaluate the performance characteristics of the CxBladder test, multiple consecutive urine samples will be collected during the course of surveillance.

Inclusion Criteria

Low-, intermediate-, and high-risk surveillance subjects with a previous confirmed diagnosis or recurrence of urothelial carcinoma within the last 3 calendar years.
Subjects must agree to 4 successive study visits, including urine sample collection at each visit.
Physically able to provide a voided urine sample (a sample from catheterization is not eligible).
Able to give written informed consent
Able and willing to comply with study requirements
Aged 18 years or older

Exclusion Criteria

Total cystectomy of the bladder, subjects with neo-bladders or illeal conduits
Previous muscle invasive bladder tumour (pT2 or greater)
Known pregnancy Deferral Criteria
Prior genitourinary manipulation (catheterisation, urethral dilation, cystoscopy, etc.) within 14 calendar days of the scheduled urine collection, study enrollment with urine sample collection for Cxbladder Monitor testing should be deferred until a minimum of 14 calendar days has passed since the procedure was performed.
Active urinary tract infection (UTI) within 14 calendar days of the scheduled urine collection, study enrollment with urine sample collection for Cxbladder Monitor testing should be deferred until the treatment is complete and the UTI is resolved.
If a subject has had intravesical immunotherapy or chemotherapy within the previous 6 weeks, study enrollment with urine sample collection for Cxbladder Monitor testing should be deferred. Study enrollment must be at least 28 calendar days post-last treatment.

This is a multi-site study recruiting subjects from Veterans Affairs and other medical

centers. Subjects will be prospectively recruited to an observational study to validate

the performance characteristics of CxBladder Monitor test (Monitor) and the

second-generation test, CxBladder Monitor Plus (Monitor+). The study will recruit low,

intermediate, and high-risk surveillance subjects, defined as per American Urological

Association (AUA) / Society of Urologic Oncology (SUO) guidelines 2016 amendment 2020,

previously diagnosed with urothelial carcinoma (UC). Eligible subjects will include those

under surveillance for recurrence of UC. A voided urine sample will be collected from

each enrolled subject at each of 4 successive surveillance visits. The collected urine

will be used for CxBladder testing and central urine cytology. The study will collect

primary tumour tissue from the first confirmed tumour, i.e., the primary diagnosis of UC

(if available) and any subsequent collections within 12 weeks. Tissue samples from any UC

recurrences while in study will also be collected to genotype each tumour using RNA or

DNA markers indicative of an elevated risk of UC. Monitor/Monitor+ results will not be

reported to patients or physicians. This study primarily aims to clinically validate the

performance characteristics (sensitivity, specificity, negative predictive value,

positive predictive value, and test-negative rate) of the Cxbladder Monitor/Monitor+ test

compared to the reference standard i.e., tumours observed by cystoscopy and confirmed by

pathology over a maximum of 4 surveillance visits. Sites are required to be competent in

recruiting and completing required test request forms, Case Report Forms (CRF) and sample

collection in a professional manner in accordance with good clinical practice (GCP).

Have a question?
We're here to help

Chat with us: LiveHelp
Call us: 1-800-4-CANCER
(1-800-422-6237)

Which trials are right for you?

Use the checklist in our guide to gather the information you’ll need.

Longitudinal Bladder Cancer Study for Tumour Recurrence

Inclusion Criteria

Exclusion Criteria

United States

Washington

Seattle

Have a question?
We're here to help

Which trials are right for you?

Longitudinal Bladder Cancer Study for Tumour Recurrence

Description

Eligibility Criteria

Locations & Contacts

Trial Objectives and Outline

Trial Phase & Type

Lead Organization

Trial IDs

Have a question?We're here to help

Which trials are right for you?

Have a question?
We're here to help